NO20064426L - Anvendelse av N-piperidinderivater til behandling av neurodegenerative patologier - Google Patents

Anvendelse av N-piperidinderivater til behandling av neurodegenerative patologier

Info

Publication number
NO20064426L
NO20064426L NO20064426A NO20064426A NO20064426L NO 20064426 L NO20064426 L NO 20064426L NO 20064426 A NO20064426 A NO 20064426A NO 20064426 A NO20064426 A NO 20064426A NO 20064426 L NO20064426 L NO 20064426L
Authority
NO
Norway
Prior art keywords
disease
pathologies
treatment
preparations
prevention
Prior art date
Application number
NO20064426A
Other languages
English (en)
Inventor
Gianfranco Merizzi
Original Assignee
Medestea Res & Production Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medestea Res & Production Spa filed Critical Medestea Res & Production Spa
Publication of NO20064426L publication Critical patent/NO20064426L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Foreliggende oppfinnelse vedrører kjemiske forbindelser, farmasøytiske preparater og veterinærpreparater, og anvendelsen av slike preparate i behandlingen eller forebyggingen av neurodegenerative patologier og syndromer, slik som- Parkinsons sykdom, Alzheimers sykdom, lesjoner som skyldes iskemi og reperfusjon, traumatiske hjerteelesjoner, -neuropati som skylder HIV, Downs syndrom, diabetisk polyneuropati, muskulær dystrofi, multippel sklerose, Huntingtons sykdom, prionsykdom, sen dyskinesi, tauopati og demyelinerende patologi, og andre livstruende patologier, slik som hjerte/nyre/pulmonær/hepatisk/ tarm-iskemireperfusjon, hypertensjon, diabetes, kreft, sjokk, toksisitet som skyldes legemidler og stråling, (radioterapi og strålingsbeskyttelse), inflammatoriske tilstander, aterosklerose, aldring, hyperlipidemi, hyperkolesterolemi, epilepsi og reumatoid artritt, der alle disse er kjent for å være assosiert med et overskudd av produksjon av reaktive, frie radikaler. Mer spesifikt vedrører foreliggende oppfinnelse preparater som inneholder sykliske (bis)-hydroksylaminantioksidanter avledet fra N-piperidin som farmasøytiske preparater til forebyggingen og behandlingen av patologier hos mennesker og dyr.
NO20064426A 2004-03-01 2006-09-29 Anvendelse av N-piperidinderivater til behandling av neurodegenerative patologier NO20064426L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000124A ITTO20040124A1 (it) 2004-03-01 2004-03-01 Nuovi impieghi in terapia di derivati di n-piperidina particolarmente per il trattamento di patologie neurodegenerative
PCT/EP2005/001818 WO2005084677A1 (en) 2004-03-01 2005-02-22 Use of n-piperidine derivatives for the treatment of neurodegenerative pathologies

Publications (1)

Publication Number Publication Date
NO20064426L true NO20064426L (no) 2006-11-29

Family

ID=34917559

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064426A NO20064426L (no) 2004-03-01 2006-09-29 Anvendelse av N-piperidinderivater til behandling av neurodegenerative patologier

Country Status (14)

Country Link
US (1) US8461186B2 (no)
EP (1) EP1727545B1 (no)
JP (1) JP2007525530A (no)
KR (1) KR101244799B1 (no)
CN (1) CN1946400B (no)
AU (1) AU2005218739A1 (no)
BR (1) BRPI0507817A (no)
CA (1) CA2556383C (no)
ES (1) ES2392846T3 (no)
IT (1) ITTO20040124A1 (no)
NO (1) NO20064426L (no)
PL (1) PL1727545T3 (no)
RU (1) RU2377986C2 (no)
WO (1) WO2005084677A1 (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1815741B1 (en) * 2006-01-19 2011-07-06 Medestea Research & Production S.p.A. Use of n-piperidine derivative compositions for protecting biological systems
US20090234150A1 (en) * 2006-07-14 2009-09-17 Peter Carmeliet Use of ppar-alpha agonists to treat skeletal muscle wasting disorders
CA2696310A1 (en) * 2007-08-14 2009-02-19 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services, The Method of treating disease involving myelin and/or axonal loss
KR101491763B1 (ko) * 2013-12-19 2015-02-16 대한민국 1-(2-((4-클로로-2-메톡시-5-메칠페닐)아미노)-2-옥소에틸)-ｎ-(2-하이드록시페닐)-피페리딘-4-카복사마이드 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 프리온 질환 예방 및 치료용 약학적 조성물
CN112126060B (zh) * 2019-06-25 2022-05-31 北京天罡助剂有限责任公司 一种聚合型高分子空间位阻胺及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4590231A (en) * 1983-10-11 1986-05-20 Ciba-Geigy Corporation Polyolefin compositions stabilized against degradation using hydroxylamine derivatives
US4665185A (en) * 1984-03-22 1987-05-12 Ciba-Geigy Corporation Process for preparing nitroxyls of sterically hindered amines
US4691015A (en) * 1984-07-23 1987-09-01 Ciba-Geigy Corporation Hydroxylamines derived from hindered amines
US4883666A (en) * 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
US5036097A (en) * 1989-10-17 1991-07-30 Oklahoma Medical Research Foundation Phenylbutyl nitrone compositions and methods for prevention of gastric ulceration
CA2072934C (en) * 1991-07-19 2007-08-28 Karl William Aston Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
US5696109A (en) * 1992-12-07 1997-12-09 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
WO1995022963A1 (en) * 1994-02-28 1995-08-31 Medinova Medical Consulting Gmbh Drug targeting system, method for preparing same and its use
ATE174915T1 (de) * 1994-10-31 1999-01-15 Merck Patent Gmbh Benzylpiperidinderivate mit hoher affinität zu bindungsstellen von aminosäure-rezeptoren
DE69425287T2 (de) * 1994-11-15 2001-03-15 Moreno Paolini N-hydroxypiperidine als superoxid-radikalfänger
US6420429B1 (en) * 1997-12-23 2002-07-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Brain targeted low molecular weight hydrophobic antioxidant compounds
AU1186300A (en) * 1998-11-25 2000-06-13 Daiichi Radioisotope Laboratories, Ltd. Drugs and reagents containing n-acyloxylated cycloalkyl compounds as the active ingredient
WO2002028390A1 (en) 2000-10-05 2002-04-11 Pharmacia Corporation Composition comprising a catalyst for the dismutation of superoxide and use of the composition for preventing and treating hypotension
EP1353655A2 (en) 2001-01-26 2003-10-22 Metaphore Pharmaceuticals Inc. Method of treatment of neurodegenerative disorders using pentaaza-macrocyclic ligand complexes
US20050065182A1 (en) * 2003-09-23 2005-03-24 Papazoglou Elisabeth S. Method and compositions for chronic wound care
WO2005032479A2 (en) * 2003-10-01 2005-04-14 Unviversity Of Florida Research Foundation, Inc. Compositions and methods for selective inhibition of nicotine acetylcholine receptors

Also Published As

Publication number Publication date
CN1946400B (zh) 2012-05-09
US8461186B2 (en) 2013-06-11
US20070191427A1 (en) 2007-08-16
KR101244799B1 (ko) 2013-03-18
ES2392846T3 (es) 2012-12-14
CN1946400A (zh) 2007-04-11
JP2007525530A (ja) 2007-09-06
CA2556383C (en) 2013-05-14
CA2556383A1 (en) 2005-09-15
EP1727545A1 (en) 2006-12-06
BRPI0507817A (pt) 2007-07-10
KR20060132746A (ko) 2006-12-21
WO2005084677A1 (en) 2005-09-15
ITTO20040124A1 (it) 2004-06-01
RU2006134643A (ru) 2008-04-10
RU2377986C2 (ru) 2010-01-10
EP1727545B1 (en) 2012-08-08
AU2005218739A1 (en) 2005-09-15
PL1727545T3 (pl) 2013-01-31

Similar Documents

Publication Publication Date Title
Mittal et al. Recent advances in the antioxidant activity and mechanisms of chalcone derivatives: A computational review
NO20076625L (no) Derivater av 4- eller 5-aminosalisylsyre
CY1117895T1 (el) Στερεα φαρμακευτικα σκευασματα που περιεχουν bibw 2992
Papadopoulou et al. Discovery of potent nitrotriazole-based antitrypanosomal agents: In vitro and in vivo evaluation
CN105120854B (zh) 新水杨酸衍生物、其药学上可接受的盐、其组合物以及其使用方法
Araujo et al. Synthesis, antibacterial evaluation, and QSAR of caffeic acid derivatives
Legin et al. Guanidine platinum (II) complexes: synthesis, in vitro antitumor activity, and DNA interactions
HRP20070076A2 (en) Pyrimidine derivatives
EA201290952A1 (ru) Химические соединения
ME00572A (en) Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
Ansari et al. Dithiolethiones: a privileged pharmacophore for anticancer therapy and chemoprevention
Prati et al. Quinones bearing non-steroidal anti-inflammatory fragments as multitarget ligands for Alzheimer’s disease
NO20064426L (no) Anvendelse av N-piperidinderivater til behandling av neurodegenerative patologier
AU2013259779B2 (en) N-ethyl-4-hydroxyl-1-methyl-5- (methyl(2,3,4,5,6-pentahydroxyhexyl) amino) -2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide
Saini et al. Characterization of four new photodegradation products of hydroxychloroquine through LC-PDA, ESI-MSn and LC-MS-TOF studies
TW200732325A (en) Organic compounds
EA200970170A1 (ru) Производные 4-триметиламмоний-3-аминобутирата и 4-триметилфосфоний-3-аминобутирата как ингибиторы срт
Pidvyshennyi et al. Acidity of saturated (hetero) cyclic α-fluoro carboxylic acids and lipophilicity of their amide derivatives
Maldonado et al. Role of allyl group in the hydroxyl and peroxyl radical scavenging activity of S-allylcysteine
Chofor et al. Synthetic fosmidomycin analogues with altered chelating moieties do not inhibit 1-deoxy-D-xylulose 5-phosphate reductoisomerase or Plasmodium falciparum growth in vitro
CY1124818T1 (el) EΝΩΣΕΙΣ AZAΪNΔOΛYΛΠYPIΔONHΣ KAI ΔlAZAΪNΔOΛYΛΠYPIΔΟNHΣ
Aputen et al. Platinum (IV) prodrugs incorporating an indole-based derivative, 5-benzyloxyindole-3-acetic acid in the axial position exhibit prominent anticancer activity
Jeong et al. Comparative metabolism of honokiol in mouse, rat, dog, monkey, and human hepatocytes
Mohanraj et al. A study on structural characterization of potential impurities of Sugammadex sodium using LC/ESI/QTOF/MS/MS and NMR
Huber et al. A novel cluster of C5-curcuminoids: design, synthesis, in vitro antiproliferative activity and DNA binding of bis (arylidene)-4-cyclanone derivatives based on 4-hydroxycyclohexanone scaffold: I. Huber et al.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application